Global Vasculitis Treatment Market 2017-2021

Overview of the global vasculitis treatment market

According to vasculitis treatment industry insights, the global vasculitis treatment market will grow at a CAGR of more than 4% during the forecast period. The provision for special drug designations is one of the key drivers that will stimulate growth in the market from 2017 to 2021. The regulatory authorities of the US and Europe have listed vasculitis as one of the rare diseases because it involves a limited patient population. This prevents the recovery of expenses that are invested in research and developmental activities for the treatment of vasculitis. As a result, the US and the European Union (EU) provide provisions for orphan drug designation of drugs to overcome this limitation. In the US, orphan drugs are offered incentives such as tax credits for clinical testing, exemption from prescription fees, and market exclusivity for seven years. To protect the sales of orphan drugs, the entry of generics is barred for the duration of market exclusivity. The orphan drug designation and approvals in Japan involves incentives in the form of financial aid. These incentives cover the costs of clinical trials and tax exemptions of up to 6% of research costs and 10% of corporate tax. These provisions will encourage manufacturers to develop novel therapies for vasculitis in the forthcoming years.

One of the key vasculitis treatment market trends that will gain traction in the vasculitis treatment market is the increase in public awareness programs. These programs develop the best-individualized treatment plan for each patient to offer an advanced care for patients with vasculitis. Also, these programs will increase awareness about autoimmune diseases, such as vasculitis, which in turn, will positively impact the market’s growth.

Competitive landscape and key vendors

The vasculitis treatment market is characterized by the presence of a few key vendors and is highly concentrated. These vendors are increasingly competing against each other based on factors such as new disease indication. The development of drugs for the treatment of RA, psoriatic arthritis, and psoriasis will strengthen the competitive environment of the market.

Key vendors in this market are 

• Bristol-Myers Squibb
• CELGENE
• F. Hoffmann-La Roche
• GlaxoSmithKline

Other prominent vendors in the market include Ablynx, AB SCIENCES, Acorda Therapeutics, Alder Biopharmaceuticals, Antares Pharma, Astellas Pharma, AstraZeneca, Baxter, Boehringer Ingelhein, Can-Fite BioPharma, Celltrion, ChemoCentryx, Coherus BioSciences, Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, Hospira, Idera, Immunomedics, ImmuPharma, Incyte, Invion, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, Merck, MedImmune, Morphotek, Novo Nordisk, Novartis, Opexa Therapeutics, Principia, Regeneron, Sandoz, Sanofi, Santarus, Takeda, UCB, Vaccinex, Vertex Pharmaceuticals, and Vitae Pharmaceuticals.

Segmentation by drug class and analysis of the vasculitis treatment market

• Corticosteroids
• Immunosuppressants
• Biologics

Biologics are large molecules that are extracted from biological sources such as humans, animals, or microorganisms. The segment is growing at a rapid pace due to the increased uptake of these drugs in developed markets such as the US and Europe. The segment will continue to grow until the end of 2021 as it includes a wide range of products such as gene therapy, recombinant proteins, somatic cells, tissues, and vaccines to treat various diseases.

Segmentation by geography and analysis of the vasculitis treatment market

• Americas
• APAC
• EMEA

Based on the vasculitis treatment market outlook, the Americas accounted for the majority of market shares during 2016 due to the growing incidence of rheumatoid vasculitis. Rheumatoid vasculitis affects the small and medium-sized blood vessels in patients. The region will continue to be accountable for the largest shares for the next four years due to the increasing demand for drugs for the treatment of rheumatoid arthritis (RA) and giant cell arteritis (GCA).

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global vasculitis treatment market?
• What are the key market trends impacting the growth of the global vasculitis treatment market?
• What are the challenges to market growth?
• Who are the key vendors in the global vasculitis treatment market?
• What are the market opportunities and threats faced by the vendors in the global vasculitis treatment market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global vasculitis treatment market?

Technavio also offers customization on reports based on specific client requirement.